New combo targets Hard-to-Treat melanoma
NCT ID NCT03131908
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining an experimental drug (GSK2636771) with the immunotherapy pembrolizumab (Keytruda) can help control metastatic melanoma in patients whose tumors have lost a protein called PTEN. The trial involves up to 41 adults with advanced melanoma that hasn't responded to prior treatment. Researchers will first find the safest dose of the combination, then measure how well it shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GSK2636771 (a PI3K-beta inhibitor) and pembrolizumab (Keytruda, an immunotherapy)
What this could lead to
If this combination works, it could offer a new treatment option for people with a specific type of melanoma that has not responded to standard therapies.
What could go wrong
This is an early-phase trial with only 27 participants, so results may not apply broadly. The combination may cause side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States